(Q51143723)

31 March 2018

title

Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer. (English)

1 reference

31 March 2018

author name string

Anthony T Corcoran

series ordinal

1

1 reference

31 March 2018

Pamela B Peele

series ordinal

2

1 reference

31 March 2018

Ronald M Benoit

series ordinal

3

1 reference

31 March 2018

language of work or name

English

0 references

publication date

9 April 2010

1 reference

31 March 2018

published in

Urology

1 reference

31 March 2018

volume

76

1 reference

31 March 2018

issue

3

1 reference

31 March 2018

page(s)

703-707

1 reference

31 March 2018

20-year outcomes following conservative management of clinically localized prostate cancer

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.071

Natural History of Early, Localized Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.071

A quantitative analysis of the costs and benefits of prostate cancer screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.071

Mortality results from a randomized prostate-cancer screening trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.071

Active surveillance for the management of prostate cancer in a contemporary cohort

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.071

What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.071

Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.071

Active surveillance for early-stage prostate cancer: review of the current literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.071

Prostate-specific antigen in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.071

Prostate specific antigen versus prostate specific antigen density as a prognosticator of pathological characteristics and biochemical recurrence following radical prostatectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.071

Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.071

Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.071

Cumulative cost pattern comparison of prostate cancer treatments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.071

The new economics of radical prostatectomy: cost comparison of open, laparoscopic and robot assisted techniques

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.071

Outcomes and follow-up strategies for patients on active surveillance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.071

Active surveillance for favorable risk prostate cancer: rationale, risks, and results

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.071

Delayed versus immediate surgical intervention and prostate cancer outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.12.071

10.1016/J.UROLOGY.2009.12.071

7 January 2021

Identifiers

DOI

1 reference

31 March 2018

1 reference

31 March 2018